Anti-CD22 and anti-CD79b antibody-drug conjugates preferentially target proliferating B cells-Reference-Cited by-同舟云学术

Anti-CD22 and anti-CD79b antibody-drug conjugates preferentially target proliferating B cells

Published:2017-03-06 Issue:8 Volume:174 Page:628-640
ISSN:0007-1188
Container-title:British Journal of Pharmacology
language:en
Short-container-title:British Journal of Pharmacology

Author:

Fuh Franklin K¹,Looney Caroline¹,Li Dongwei²,Poon Kirsten A³⁴,Dere Randall C⁵,Danilenko Dimitry M⁶,McBride Jacqueline¹,Reed Chae⁵,Chung Shan⁵,Zheng Bing⁷,Mathews William Rodney¹,Polson Andrew⁷,Prabhu Saileta²,Williams Marna¹⁸

Affiliation:

1. Department of Pharmacodynamic Biomarkers; Genentech, Inc.; South San Francisco CA USA

2. Department of Pharmacokinetic and Pharmacodynamic Sciences; Genentech, Inc.; South San Francisco CA USA

3. Department of Safety and Toxicology; Genentech, Inc.; South San Francisco CA USA

4. Denali Therapeutics, Inc.; South San Francisco CA USA

5. Department of BioAnalytical Research and Development; Genentech, Inc.; South San Francisco CA USA

6. Department of Safety Assessment; Genentech, Inc.; South San Francisco CA USA

7. Department of Immunology Research; Genentech, Inc.; South San Francisco CA USA

8. MedImmune, Gaithersburg; MD USA

Publisher

Wiley

Subject

Pharmacology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/bph.13697/fullpdf

Reference30 articles.

1. Phase I study of the anti-CD22 antibody-drug conjugate pinatuzumab vedotin with/without rituximab in patients with relapsed/refractory B-cell non-Hodgkin's lymphoma;Advani;Clin Cancer Res,2016

2. The Concise Guide to PHARMACOLOGY 2015/16: Overview;Alexander;Br J Pharmacol,2015

3. Trial watch: phase III and submission failures: 2007-2010;Arrowsmith;Nat Rev Drug Discov,2011

4. Trial watch: phase II and phase III attrition rates 2011-2012;Arrowsmith;Nat Rev Drug Discov,2013

5. Evaluating the use of antibody variable region (Fv) charge as a risk assessment tool for predicting typical cynomolgus monkey pharmacokinetics;Bumbaca Yadav;J Biol Chem,2015

Cited by 20 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Clinical pharmacology strategies to accelerate the development of polatuzumab vedotin and summary of key findings;Advanced Drug Delivery Reviews;2024-02

2. Preparing for CAR T cell therapy: patient selection, bridging therapies and lymphodepletion;Nature Reviews Clinical Oncology;2022-03-22

3. Nanomedicines in B cell-targeting therapies;Acta Biomaterialia;2022-01

4. Pseudoprogression of triple-hit diffuse large B-cell lymphoma following polatuzumab vedotin-based salvage therapy;Leukemia & Lymphoma;2021-03-15

5. Polatuzumab vedotin, an anti-CD79b antibody–drug conjugate for the treatment of relapsed/refractory diffuse large B-cell lymphoma;Future Oncology;2021-01